- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes ; day:20 ; month:2 ; year:2019 ; pages:1-14
Diabetes therapy ; (20.2.2019), 1-14
- Creator
-
Overgaard, Rune V.
Delff, Philip H.
Petri, Kristin C. C.
Anderson, Thomas W.
Flint, Anne
Ingwersen, Steen H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-019-0581-y
- URN
-
urn:nbn:de:101:1-2019032014372910552173
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Overgaard, Rune V.
- Delff, Philip H.
- Petri, Kristin C. C.
- Anderson, Thomas W.
- Flint, Anne
- Ingwersen, Steen H.
- SpringerLink (Online service)
Other Objects (12)
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Response to semaglutide of non-drinker subjects with type 2 diabetes
Semaglutide
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Response to semaglutide of non-drinker subjects with type 2 diabetes
Semaglutide
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Response to semaglutide of non-drinker subjects with type 2 diabetes
Semaglutide
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes